Robotic magnetic catheter takes aim at stubborn heart rhythms in adults born with heart defects
NCT ID NCT07812818
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Adults with congenital heart disease often develop supraventricular tachycardia, a fast or irregular heartbeat that can be hard to treat because of unusual heart anatomy or prior surgeries. This study follows 40 adults who have a cardiac ablation procedure using the MAGiC ablation catheter, which a robotic magnetic system steers through the heart. Researchers track whether the procedure stops the targeted arrhythmia right away and whether it stays gone for six months, while recording any device or procedure related safety problems. Participants visit their doctor at one week, one month, and six months after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cardiac ablation using the MAGiC ablation catheter guided by a robotic magnetic system
- What this could lead to
- If it works, doctors could have a clearer picture of whether robotic magnetic ablation reliably controls supraventricular tachycardia in adults whose congenital heart disease makes standard catheter access difficult.
- What could go wrong
- This is a small post-approval study of 40 people, so it may not capture rare complications or show how the approach performs across the wide range of congenital heart defects. Ablation carries risks of bleeding, vessel injury, or heart rhythm problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Any patients requiring an ablation procrdure for the treatment of SVT with CHD where there is limited vascular ascess or difficult to access the target cardiac chamber
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult (aged 18 or older at time of consent). * Clinically indicated for catheter ablation of a supraventricular tachycardia (macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia) * History of congenital heart disease with anatomic abnormalities and/or previous surgical interventions and/or previous surgical interventions that limit vascular or target chamber access by conventional manual catheter navigation. * Willing and capable of attending scheduled follow up visits for the study duration = Willing and able to provide informed consent. Exclusion Criteria: * Atrial fibrillation is the target arrhythmia for the catheter ablation. * Unable to be safely exposed to the level of magnetic fields used for Robotic Magnetic Navigation * A history of sensitivity to foreign objects (gold, platinum/iridium, Pebax materials) or extreme allergies. * Acute illness or active systemic infection. * Histological or anatomical abnormalities that may lead to post-operative complications including diminished resistance to infection. * Hemodynamic instability (to an extent that would make an interventional procedure high risk). * Presence of intracardiac thrombus. * Where MAGiC would need to cross a prosthetic valve. * Where MAGiC would need to be used in the coronary arteries. * Unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation. * Acute myocardial infarct (within the previous 30 days). * Unstable angina at the time of enrollment. * History of embolism (cerebrovascular accident, transient ischemic attack, systemic embolism) in the previous 30 days. * Previous cardiac ablation within the last 30 days. * Inaccessible for follow-up visits for 6 months post ablation. * Significant uncontrolled or unstable medical problems which, in the opinion of the Investigator, would preclude enrollment in and completion of the study. * Any reason or condition that, in the judgement of the investigator, makes the subject ineligible for the investigation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Congenital heart disease (CHD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A second chance for the thymus: could reimplanting it during heart surgery shield immunity?
- Could waiting longer to clamp the cord boost outcomes for babies with heart defects?
- AI reads heart scans to predict which children will develop serious complications
- Play therapy may calm young heart patients before surgery
- Which SVT drug do patients prefer? small study aims to find out
- New 3D mapping may cut radiation during heart procedure